Replies to post #5570 on Entremed (ENMD)

[Stock]

maybe Joe Kernan will do a special little dance one day for ENMD shareholders lol

[KAEPSKAG]

"I've been following this company for a long time, and have been an investor for going on four years, and the most significant impression I have about EntreMed's management is that they're more about keeping the flow going and keeping their high paying jobs than anything else."

If one looks at the progress that ENMD has made in the past 4 years, and especially since Burns became the CEO in 2004, the evidence is clearly overwhelming that ENMD intends to become a FULL-FLEDGED in the clinic company ( i.e.: sell drugs to doctors for every-day use in human patients).
There were missteps by the initial management teams- sales of Thalomid, etc.; there was hype in the May 1998 NYTimes front page article (not of ENMD's making); there was a subsequent insane PPS rise (also resulting from general biotech mania at the time); there has been subsequent loss of confidence and veracity in the company and it's affairs; there have been chronic money problems (lack of financing, necessitating dilution by further private and public placements); there has been virtually no following by Wall Street, especially by "influential" parties, and perhaps lastly: drug research, finding of appropriate compounds for IND submission, and the time it takes to pursue&complete human clinical trials&then subsequent submission of an NDA with approval(or disapproval) by the FDA takes Herculean patience.
We are finally on our way: now all we need to show is human efficacy!

[KAEPSKAG]

"This would explain why EntreMed is so much slower to act agressively in its own interest than other successful companies like Celgene and Elan.

Do we live in a world where people are more concerned with the status quo than the health and well being of millions of suffering human beings? You bet we do."

A terse reply: MONEY TALKS!
and to pursue its goals, Entremed has had no money or very little money to date.

[RRGY2K]

"EntreMed investors should realize that the company may be more about keeping itself in business by being a research company than in actually bringing products to market. Is this an unreasonalbe thought or fear on my part?"

The thoughts and fears you express are pretty unreasonable.

Hey, what exactly would you expect a clinical stage biopharmaceutical company to look like? Ten years ago, Celgene was a company holding nothing better than an orphan drug approval for Thalidomide to treat leprosy. Not to demean leprosy patients, but there just aren't enough of them to make that business very interesting to anybody.

A "research" company... is that like when there's some key guy with a big ego telling you how smart he is and how great his discoveries are going to be for all mankind (please point out a press release that suggests ENMD has anybody like that on the payroll)? Only an idiot could look at a list of 14 active ongoing trials and conclude that the company is not actively trying to bring drugs to market. See, research is in a lab somewhere, not out there in the clinic with real patients, and real patients have real doctors who will publish real results for all the world to read. All that would be a huge risk for a "research company."

Celgene is a stockholder and a partner. Entremed success is to their benefit. Thanks in part to Celgene's investments in Entremed, Panzem research continues to proceed. There's no evidence of Celgene or anyone else stalling anything.

Helpwanted, it's possible that you're an intelligent fellow, but your Fears, Uncertainties, and Doubts are in conflict with that hypothesis unless you're here with a disingenuous agenda.